Choosing glucose-lowering medication in those with established ASCVD, HF, and CKD. CV, cardiovascular; DPP-4i, dipeptidyl peptidase 4 inhibitor; GLP-1.

Slides:



Advertisements
Similar presentations
Ambulatory Treatment of Type 2 Diabetes in the U.S., 1997–2012 Featured Article: Lydia W. Turner, David Nartey, Randall S. Stafford, Sonal Singh, and G.
Advertisements

Treatment Advances in Type 2 Diabetes Panhandle Nurse Practitioner Symposium April 11, 2015 Dr. Caleb Kim.
Adding Prandial Insulin to Basal Insulin: Key Challenges
Date of download: 9/17/2016 Copyright © 2016 American Medical Association. All rights reserved. From: Insulin Therapy for Type 2 Diabetes Mellitus JAMA.
Copyright © 2015 by the American Osteopathic Association.
Copyright © 2015 by the American Osteopathic Association.
Copyright © 2015 by the American Osteopathic Association.
NATURAL HISTORY OF BETA CELL FAILURE IN T2DM
James Thrasher, MD  The American Journal of Medicine 
Copyright © 2015 by the American Osteopathic Association.
From: Diabetes Medications as Monotherapy or Metformin-Based Combination Therapy for Type 2 DiabetesA Systematic Review and Meta-analysis Ann Intern Med.
Copyright © 2015 by the American Osteopathic Association.
Copyright © 2015 by the American Osteopathic Association.
Stuart A. Ross, MB CHB, FRACP, FRCP(C) 
Global Projections for Diabetes:
Updates on Outcomes for Novel T2D Therapies
Antihyperglycemic therapy in type 2 diabetes: general recommendations.
Clinical Application of Incretin-Based Therapy: Therapeutic Potential, Patient Selection and Clinical Use  David M. Kendall, MD, Robert M. Cuddihy, MD,
Clinical Application of New CV Outcomes Data
Options for Combination Therapy in Type 2 Diabetes: Comparison of the ADA/EASD Position Statement and AACE/ACE Algorithm  Timothy Bailey, MD  The American.
James Thrasher, MD  The American Journal of Medicine 
Figure 3 Putative actions of glucagon-like peptide 1 (GLP-1)
Diabetes and CV Risk Reduction: Cardiologists’ Perspectives on the Latest Outcomes Data.
Antihyperglycemic therapy in type 2 diabetes: general recommendations.
2008 FDA Guidance. Working as a Team for Cardiovascular Risk Reduction in Patients With T2D.
Antihyperglycemic therapy in type 2 diabetes: general recommendations
Antihyperglycemic therapy in type 2 diabetes: general recommendations (17). Antihyperglycemic therapy in type 2 diabetes: general recommendations (17).
Average patient profile in terms of (A) previous therapy drug class and (B) complexity of previous regimen. Average patient profile in terms of (A) previous.
T2DM, CV Safety, and Efficacy: DPP-4 Inhibitors in focus
Antihyperglycemic therapy in type 2 diabetes: general recommendations.
Antihyperglycemic Therapy
Antihyperglycemic therapy in type 2 diabetes: general recommendations.
Individualizing Insulin Therapy in the Management of Type 2 Diabetes
Case Challenges: Early and Intensive Type 2 Diabetes Treatment With Modern Agents.
Predicted and observed HbA1c levels using doubly robust estimation adjusting for either a comprehensive set of confounders (left panel) or a set of confounders.
Approach to starting and adjusting insulin in type 2 diabetes.
A New Drug Target for Type 2 Diabetes
Changes in A1C (A), body weight (B), and systolic blood pressure (C) with canagliflozin in combination with incretin-based therapies. *In the dose-advancement.
Patient Selection for Modern T2D Agents
Trends in the relative contribution of each second-line diabetes medication class, by quarter, as a percent of all second-line prescribing, 2011–2015.
Figure 1 Sites of action of glucose-lowering agents
Kaplan-Meier plot of incident CVD according to the treatment group over a 4-year period following intensification of diabetes therapy. Kaplan-Meier plot.
Predicted and observed BMI levels using doubly robust estimation adjusting for either a comprehensive set of confounders (left panel) or a set of confounders.
CardioDiabetes: Core Competencies for Cardiovascular Clinicians in a Rapidly Evolving Era of Type 2 Diabetes Management  G. B. John Mancini, MD, Alice.
ADA/EASD general recommendations for type 2 diabetes management (1).
Kaplan-Meier plots of hHF: DPP-4i and SU cohort with baseline CVD (panel A); saxagliptin and sitagliptin cohorts with baseline CVD (panel B); DPP-4i and.
Results of sensitivity analyses.
Glycaemic management of type 2 diabetes
CANVAS programe subanalyses HR (95%CI): 0.65 ( ) ( ) ( ) ( )
eGFR ‘cut-offs’ for glucose lowering therapies
T2DM patients with HF may benefit from SGLT2 inhibitor therapy
Changes (mean +SEM) in glucose, insulin, glucagon-like peptide (GLP)-1 and ghrelin from the baseline values after administration of placebo (broken lines.
Glucose-lowering medication in type 2 diabetes: overall approach.
Observed RW, modeled, and published trial estimates of HbA1c change from baseline. Observed RW, modeled, and published trial estimates of HbA1c change.
Showing significant positive correlation of circulating plasma DPP4 levels with total intra-abdominal adipose tissue volume in patients with T2DM (A) and.
What's New in Oral Combination Therapy for Type 2 Diabetes?
Multilevel Intervention Most scientific proof about developing health and health patronage.
Antihyperglycemic therapy in type 2 diabetes: general recommendations (22). Antihyperglycemic therapy in type 2 diabetes: general recommendations (22).
Metabolic parameters in the three groups of patients during l-arginine infusion. Metabolic parameters in the three groups of patients during l-arginine.
Comorbid conditions and concomitant medications.
ADA type 2 diabetes glycemic control algorithm, reproduced with permission from ref. 4. *Usually a basal insulin (neutral protamine Hagedorn, glargine,
Plasma glucose (A), serum insulin (B), serum C peptide (C) and plasma GLP-1 level (D) during the 2-hour OGTT among subjects with normal glucose tolerance.
Postprandial glucose, insulin and glucagon-like peptide-1 (GLP-1) levels following carbohydrate-first (CF), carbohydrate-last (CL) and sandwich (S) meal.
Comment on “Oral diabetes medications other than dipeptidyl peptidase-4 inhibitors are not associated with bullous pemphigoid: A Finnish nationwide case-control.
Patient disposition and study protocol.
Renal licences of commonly used anti-diabetes drugs
Antihyperglycemic therapy in adults with type 2 diabetes
Glucose-lowering medication in type 2 diabetes: overall approach.
Fig. 1. Antihyperglycemic therapy algorithm for adult patients with type 2 diabetes mellitus (T2DM). The algorithm stratifies the choice of medications.
Glucagon-Like Peptide-1 Receptor (GLP-1R) Agonists and Dipeptidyl Peptidase-4 (DPP-4) Inhibitors: How Do They Exert Their Metabolic Actions? Part 5.
Presentation transcript:

Choosing glucose-lowering medication in those with established ASCVD, HF, and CKD. CV, cardiovascular; DPP-4i, dipeptidyl peptidase 4 inhibitor; GLP-1 RA, glucagon-like peptide 1 receptor agonist; SGLT2i, SGLT2 inhibitor; SU, sulfonylurea. Choosing glucose-lowering medication in those with established ASCVD, HF, and CKD. CV, cardiovascular; DPP-4i, dipeptidyl peptidase 4 inhibitor; GLP-1 RA, glucagon-like peptide 1 receptor agonist; SGLT2i, SGLT2 inhibitor; SU, sulfonylurea. Melanie J. Davies et al. Dia Care 2018;41:2669-2701 ©2018 by American Diabetes Association

Feedback: Privacy Policy Feedback
Do Not Sell My Personal Information
About project: SlidePlayer Terms of Service

© 2025 SlidePlayer.com. Inc. All rights reserved.